tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Boratyńska M et al. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. 2006 Ann. Transplant. pmid:17494290
Foroncewicz B et al. A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. 2013 Ann. Transplant. pmid:23896824
Grochowiecki T et al. A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. 2006 Ann. Transplant. pmid:17494291
Mocchegiani F et al. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. 2014 Ann. Transplant. pmid:25347718
Hakeam HA et al. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. 2008 Ann. Transplant. pmid:18566560
Bäckman L and Persson CA An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. 2014 Ann. Transplant. pmid:24637379
Steinebrunner N et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. 2014 Ann. Transplant. pmid:24457606
Urbanowicz T et al. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. 2014 Ann. Transplant. pmid:25274118
Czubkowski P et al. Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation. 2014 Ann. Transplant. pmid:25409773
Baron PW et al. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. 2017 Ann. Transplant. pmid:28533501
Tanaka T et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. 2013 Ann. Transplant. pmid:23792533
Ueda K et al. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. 2014 Ann. Transplant. pmid:24535029
Augusto JF et al. Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. 2013 Ann. Transplant. pmid:23872516
Miyata Y et al. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. 2016 Ann. Transplant. pmid:27503662
Mizuno S et al. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. 2013 Ann. Transplant. pmid:23845965
Herden U et al. Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:26842532
Kuypers DR Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. 2008 Ann. Transplant. pmid:18806728
Grenda R et al. Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients--a retrospective study. 2009 Jul-Sep Ann. Transplant. pmid:19644155
Basu A et al. Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. 2011 Jul-Sep Ann. Transplant. pmid:21959503
Fukazawa K et al. Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. 2011 Jul-Sep Ann. Transplant. pmid:21959523
Bułanowski M et al. Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. 2012 Jul-Sep Ann. Transplant. pmid:23018257
Schmid S et al. Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection. 2014 Ann. Transplant. pmid:25123847
Baran DA and Galin ID "One size fits all": immunosuppression in cardiac transplantation. 2003 Ann. Transplant. pmid:12848376
Ogura Y et al. Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:27432248
Dedinská I et al. Waist circumference as an independent risk factor for NODAT. 2015 Ann. Transplant. pmid:25791039
Eguchi S et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. 2007 Ann. Transplant. pmid:18344932
WÅ‚odarczyk Z et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. 2002 Ann. Transplant. pmid:12465429
Matia I et al. Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. 2014 Ann. Transplant. pmid:24815872
Park S et al. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. 2018 Ann. Transplant. pmid:29891834
Provenzani A et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. 2009 Jan-Mar Ann. Transplant. pmid:19289993
Fuchs U et al. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. 2014 Ann. Transplant. pmid:24953848
Hošková L et al. Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. 2016 Ann. Transplant. pmid:27226081
Abdel Halim M et al. Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. 2010 Jan-Mar Ann. Transplant. pmid:20305320
Wu P et al. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. 2011 Jan-Mar Ann. Transplant. pmid:21436775
Foroncewicz B et al. Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. 2014 Ann. Transplant. pmid:25163829
Bösmüller C et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. 2012 Ann. Transplant. pmid:23274323
Olczak-Kowalczyk D et al. The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. 2012 Ann. Transplant. pmid:23274327
Zakliczyński M et al. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. 2005 Ann. Transplant. pmid:16218032
Schnitzbauer AA et al. Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation. 2015 Ann. Transplant. pmid:25553853
Mahalati K and Kahan BD Pharmacological surrogates of allograft outcome. 2000 Ann. Transplant. pmid:11217202
Van Laecke S et al. Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. 2017 Ann. Transplant. pmid:28848225
Malinowski M et al. The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. 2009 Apr-Jun Ann. Transplant. pmid:19487793
Kitazawa F et al. Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. 2017 Ann. Transplant. pmid:28947731
Hirano Y et al. Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation. 2017 Ann. Transplant. pmid:28798289
Duvoux C et al. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. 2015 Ann. Transplant. pmid:25588713
Mijal J et al. Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. 2002 Ann. Transplant. pmid:12854345
Albano L et al. Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. 2016 Ann. Transplant. pmid:27122116
Thölking G et al. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. 2016 Ann. Transplant. pmid:27003330
Snell GI et al. Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. 2013 Ann. Transplant. pmid:23921892
Wyzgał J et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. 2007 Ann. Transplant. pmid:18173063